Navigation Links
Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
Date:12/10/2009

EMERYVILLE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an Analyst Briefing on December 17, 2009 at 8:30 a.m. ET.

The briefing, hosted by Onyx management, will provide an overview of its development program and feature presentations on multiple tumor types by external clinical investigators and members of management.

The live webcast, to begin at 8:30 a.m. ET, will be available on the Onyx website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

A replay of the webcast will be available on the Onyx website through December 31, 2009.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
2. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
3. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
4. Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lees Pharmaceuticals
5. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
6. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
7. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
8. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
11. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
(Date:5/10/2017)... CSSi, the global leader in patient recruitment, ... is proud to announce the launch of its newly ... both enriched content and a customized layout that provides ... already well-established position as the top global patient recruitment ... months of hard work, we are delighted to officially ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
Breaking Medicine Technology:
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... As a ... knows the importance of prostate cancer screenings. Early detection of the disease, he ... of robotic surgery at Georgia Urology , stands alongside the Georgia Comprehensive Cancer ...
(Date:5/19/2017)... ... May 18, 2017 , ... CloSYS products which are marketed as ... extremely helpful for mouth and gum health, which is linked to one’s overall health. ... learned quickly of the powerful ways in which CloSYS products immediately helped eliminate bad ...
(Date:5/19/2017)... ... May 18, 2017 , ... Somnoware, a leading provider of digital health ... independently dispense CPAP devices and supplies, such as machines, filters, tubing, and masks. Using ... devices. Device registration for daily usage data is automated, and a DME order is ...
(Date:5/18/2017)... ... , ... Originally launched to market as the EPIK Learning Tab, the highly ... expansion of their product line, the company believed it was the right time to ... will be any tablet product sold by EPIK Learning. This year there will ...
(Date:5/18/2017)... ... May 18, 2017 , ... The nZone’s Adrenaline Bootcamp is ... organization which sponsors numerous programs and activities aimed at supporting and honoring our ... Day Weekend. , The MURPH Challenge, named after LT. Michael P. Murphy ...
Breaking Medicine News(10 mins):